Table 2.
Results of the three independent ELISA studies of the binding activity of the optimum nivolumab-loaded GNPs when compared to free nivolumab as a reference using non-linear regression with five parameters.
| Best-Fit Value | Run 1 | Run 2 | Run 3 |
|---|---|---|---|
| EC50 | 0.039 ± 0.592 | 0.057 ± 0.596 | 0.057 ± 0.594 |
| Relative potency (binding activity) | 99.42% | 95.42% | 92.14% |
| Goodness of Fit (R2) | 0.997 | 0.995 | 0.997 |
| Hillslope | 2.698 | 2.558 | 2.061 |
| S | 0.371 | 0.477 | 0.656 |
| Top | 3.169 | 2.752 | 2.823 |
| Bottom | 0.085 | 0.149 | 0.143 |
| Log EC50 | −1.406 | −1.245 | −1.247 |